Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valacyclovir versus valganciclovir prophylaxis after kidney transplantation
ACTRN12610000016033Phase 4Completed
- Sponsor
- Tomas Reischig, M.D., Ph.D.
- Start
- Nov 2007
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of valaciclovir and valganciclovir in cytomegalovirus disease (CMV) (2 arms), sponsored by Tomas Reischig, M.D., Ph.D. Primary endpoints: Active cytomegalovirus infection, Biopsy-proven acute rejection and 1 more. Started Nov 2007; status: completed.
02
Drugs
valaciclovirvalganciclovir
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on ACTRN12610000016033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12610000016033.